Back to Journals » Journal of Hepatocellular Carcinoma » Volume 7

Drug-eluting Bead-Transcatheter Arterial Chemoembolization for Advanced Hepatocellular Carcinoma Refractory to Conventional Lipiodol-based Transcatheter Arterial Chemoembolization

Authors Kobayashi S, Tajiri K, Murayama A, Entani T, Futsukaichi Y, Nagata K, Takahashi K, Yasuda I

Received 25 July 2020

Accepted for publication 3 September 2020

Published 14 October 2020 Volume 2020:7 Pages 181—189

DOI https://doi.org/10.2147/JHC.S273929

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Dr Ahmed Kaseb


Saito Kobayashi, Kazuto Tajiri, Aiko Murayama, Toshiki Entani, Yuka Futsukaichi, Kohei Nagata, Kosuke Takahashi, Ichiro Yasuda

Department of Gastroenterology, Toyama University Hospital, Toyama, Japan

Correspondence: Kazuto Tajiri
Department of Gastroenterology, Toyama University Hospital, 2630 Sugitani, Toyama 930-0194, Japan
Tel +81-76-434-7301
Fax +81-76-434-5027
Email tajikazu@med.u-toyama.ac.jp

Purpose: To evaluate the potential of drug-eluting bead (DEB)-transcatheter arterial chemoembolization (TACE) as a treatment option for patients with refractory to conventional lipiodol-based TACE (c-TACE) especially with decreased liver function.
Patients and Methods: We retrospectively evaluated the treatment results of DEB-TACE for 89 HCC nodules in 27 patients with c-TACE refractory according to liver function.
Results: Although overall survival was significantly better in Child–Pugh A patients than in Child–Pugh B patients (median survival time, MST: 561 vs 347 days, p=0.031), progression-free survival was almost similar in both patients between Child–Pugh A and B (MST: 79 vs 87 days, p=0.534). Regarding antitumor response, the objective response rate (ORR) and disease-control rate (DCR) were 5.3/12.5% and 52.7/87.5% in Child–Pugh A/B, respectively. In each 89 HCC nodules, ORR and DCR were almost similar between Child–Pugh A and B (ORR, 20.3 vs 13.3%; DCR, 77.0 vs 73.3%, respectively). Adverse events of DEB-TACE were well-tolerated, and liver function was reserved during DEB-TACE procedures.
Conclusion: DEB-TACE could be a therapeutic option for advanced HCC patients with c-TACE refractory and decreased liver function.

Keywords: TACE-refractory, drug-eluting bead, post-embolization syndrome, microsphere, tyrosine kinase inhibitor

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]